An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants

Nagy Adel Youssef, Christine E. Marx, Daniel W. Bradford, Sandra Zinn, Michael A. Hertzberg, Jason D. Kilts, Jennifer C. Naylor, Marian I. Butterfield, Jennifer L. Strauss

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.

Original languageEnglish (US)
Pages (from-to)191-196
Number of pages6
JournalInternational Clinical Psychopharmacology
Volume27
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Veterans
Post-Traumatic Stress Disorders
Antidepressive Agents
Aripiprazole
Outcome Assessment (Health Care)
Interviews
Depression
Equipment and Supplies
Wounds and Injuries
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Randomized Controlled Trials
Clinical Trials
Safety

Keywords

  • Veterans
  • antipsychotic agents
  • aripiprazole
  • clinical trial
  • post-traumatic stress disorder
  • therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. / Youssef, Nagy Adel; Marx, Christine E.; Bradford, Daniel W.; Zinn, Sandra; Hertzberg, Michael A.; Kilts, Jason D.; Naylor, Jennifer C.; Butterfield, Marian I.; Strauss, Jennifer L.

In: International Clinical Psychopharmacology, Vol. 27, No. 4, 01.07.2012, p. 191-196.

Research output: Contribution to journalArticle

Youssef, Nagy Adel ; Marx, Christine E. ; Bradford, Daniel W. ; Zinn, Sandra ; Hertzberg, Michael A. ; Kilts, Jason D. ; Naylor, Jennifer C. ; Butterfield, Marian I. ; Strauss, Jennifer L. / An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. In: International Clinical Psychopharmacology. 2012 ; Vol. 27, No. 4. pp. 191-196.
@article{e7c9393ab68241a9858da674fc5fb920,
title = "An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants",
abstract = "Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.",
keywords = "Veterans, antipsychotic agents, aripiprazole, clinical trial, post-traumatic stress disorder, therapeutics",
author = "Youssef, {Nagy Adel} and Marx, {Christine E.} and Bradford, {Daniel W.} and Sandra Zinn and Hertzberg, {Michael A.} and Kilts, {Jason D.} and Naylor, {Jennifer C.} and Butterfield, {Marian I.} and Strauss, {Jennifer L.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1097/YIC.0b013e328352ef4e",
language = "English (US)",
volume = "27",
pages = "191--196",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants

AU - Youssef, Nagy Adel

AU - Marx, Christine E.

AU - Bradford, Daniel W.

AU - Zinn, Sandra

AU - Hertzberg, Michael A.

AU - Kilts, Jason D.

AU - Naylor, Jennifer C.

AU - Butterfield, Marian I.

AU - Strauss, Jennifer L.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.

AB - Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.

KW - Veterans

KW - antipsychotic agents

KW - aripiprazole

KW - clinical trial

KW - post-traumatic stress disorder

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84862116033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862116033&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e328352ef4e

DO - 10.1097/YIC.0b013e328352ef4e

M3 - Article

C2 - 22475888

AN - SCOPUS:84862116033

VL - 27

SP - 191

EP - 196

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 4

ER -